Inside Peptides
Search
Menu

CJC-1295

What it is. What the evidence says.

A synthetic peptide designed to tell the pituitary gland to release more growth hormone, which can also raise the hormone IGF-1.

Early Human EvidenceUnapproved

Predominant research setting. Clinical confidence is claim-specific.

Updated Scientific review pending
Start with the basics Regulatory status ↓
Sequence diagram and chemical structure information for CJC-1295.
CJC-1295 Chemical Structure & Sequence · Inside Peptides Scientific Library
Compound
CJC-1295 (Tetrasubstituted GHRH 1-29)
Human effectiveness
Raised GH and IGF-1 in healthy adults in early clinical studies; no approved medical use
Regulatory status
Unapproved Compound
START HERE · PLAIN LANGUAGE

CJC-1295: the basics

What is it?

A synthetic peptide designed to tell the pituitary gland to release more growth hormone, which can also raise the hormone IGF-1.

Research paper 1 ↗Research paper 2 ↗

What do people claim it helps with?

Muscle gain, fat loss, better recovery and anti-aging effects. Raising hormone levels alone does not prove these benefits.

What has research actually shown?

Short controlled studies in healthy adults found higher growth hormone and IGF-1 levels. They did not establish better strength, injury healing or a longer life.

Research paper 1 ↗Research paper 2 ↗

Has this been demonstrated in people?

Early human hormone-response studies, alongside laboratory research. Long-term clinical benefits and safety are not established.

Research paper 1 ↗Research paper 2 ↗

What side effects, risks and unknowns should I understand?

FDA reports increased heart rate and flushing-related reactions. Longer-term effects of hormone stimulation remain uncertain.

FDA safety information 1 ↗FDA briefing 2 ↗

Is it an approved medicine?

No FDA-approved medicine contains this peptide. Availability online or through a clinic does not mean it has been approved.

FDA safety information 1 ↗FDA briefing 2 ↗

Approval here means U.S. FDA approval and applies to a particular product, formulation and use. This is a starting overview, not a complete side-effect list. Sources checked 10 October 2026; independent scientific review pending.

How is it used or studied?

Studied using specific research preparations. There is no FDA-approved treatment formulation; an online vial, capsule or spray is not necessarily the product used in a study.

Different routes and formulations can have different effects. A study of one product does not validate every product with the same peptide name.

A common misunderstanding

CJC-1295 with DAC and products called “CJC-1295 without DAC” are not the same preparation.

What should I ask a clinician?
  • What diagnosis or goal are we trying to address, and what established options are available?
  • Was the expected benefit shown in people like me, using this exact product?
  • How could my medicines, health conditions or pregnancy plans affect the risks?
  • What monitoring is needed, and what would tell us the treatment is helping or should be stopped?
What do the research words mean?
Peptide
A short chain of amino acids, the building blocks of proteins.
Preclinical
Research in cells, tissues or animals before dependable treatment evidence in people.
Controlled trial
A study comparing a treatment with another treatment or a placebo to help separate its effects from other explanations.
Biomarker
A measurement, such as a hormone level. A change does not necessarily mean someone feels better or lives longer.
THE AVAILABLE RESEARCH

CJC-1295 Evidence & Clinical Profile

Human Clinical Evidence

Human Study Limits

CJC-1295 has been investigated in clinical contexts. Patient outcomes must be evaluated against study size, design, and control cohorts.

Preclinical & Pharmacological Data

Laboratory & In Vivo Assays

Cellular and animal disease models examine receptor binding affinities and signaling cascades, which require human confirmation.

Understand our evidence labels →

IDENTITY & STRUCTURE

What is CJC-1295?

Modified GRF (1-29) / Tetrasubstituted GHRH is A synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions and an optional Drug Affinity Complex (DAC). A Phase 2 trial in HIV-associated visceral obesity was registered as terminated, with no results posted. Aliases include: DAC:GRF, Modified Growth Hormone Releasing Factor, Tetrasubstituted GHRH(1-29).

Chemical sequence and molecular parameters of CJC-1295
Primary sequence schematic · Inside Peptides Molecular Database
Chemical reference
Sequence (one-letter)
Y-D-Ala-EDAIFTQSYRKVLAQLSARKLLQDI-LSR-NH2
Molecular formula
C165H269N47O46
Molecular weight
3647.2 g/mol (PubChem computed)
CAS Number
446262-90-4
UNII Code
62RC32V9N7
PubChem CID
91971820

Identifiers refer to CJC-1295 with the DAC albumin-binding group (FDA GSRS and PubChem). Products sold as "CJC-1295 without DAC" are modified GRF(1-29): CAS 863288-34-0, C152H252N44O42, 3367.9 g/mol.

Identifiers checked against PubChem and FDA's Global Substance Registration System on 13 October 2026. FDA substance record ↗ · PubChem record ↗ See all names and codes in the peptide name index.

HUMAN RESEARCH

Clinical Trials & Human Cohorts

Human research can examine tolerability, symptoms or patient outcomes. The design and comparator determine what each result can establish.

Two randomized placebo-controlled double-blind ascending-dose trials2006

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults [1]

n = not stated in abstractHealthy adults aged 21–61; trial durations of 28 and 49 days

What was reported

A single injection produced dose-dependent increases in mean GH (2- to 10-fold for 6 days or more) and IGF-I (1.5- to 3-fold for 9–11 days); after multiple doses IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported.

What limits the conclusion

Short-term study in healthy adults without clinical disease endpoints.

Read primary source ↗ (external website)
MECHANISMS OF ACTION

How the compound may work

Mechanisms describe how CJC-1295 may affect biological processes. Laboratory findings and patient outcomes answer different questions.

01
Human pharmacokinetics

Long-Acting GHRH Analogue

Acts as a long-acting GHRH analogue; the estimated half-life after subcutaneous administration was 5.8–8.1 days, with sustained GH and IGF-I increases. [1]

RESEARCH AREAS

Areas Being Studied

These research topics reflect active areas of scientific exploration, distinct from unverified commercial marketing claims.

Phase 1 clinical pharmacology

Growth Hormone Axis Stimulation

Sustained, dose-dependent GH and IGF-I increases in healthy adults. [1]

Terminated Phase 2 registry record

HIV-Associated Visceral Obesity

A 12-week placebo-controlled trial was registered and later terminated; no results are posted. [2]

AT A GLANCE

Compare the study designs.

Overview of Key CJC-1295 Studies: clinical and preclinical records
Study Design / sample Outcome type Key limitation
Phase 1 Healthy Volunteers · 2006 [1] Two randomized placebo-controlled double-blind ascending-dose trials
n = not stated in abstract		 Clinical endpoint evaluation Short-term study in healthy adults without clinical disease endpoints.
FDA & SAFETY

Regulatory Status & Clinical Safety

Regulatory Classification

Unapproved investigational substance. S2 Prohibited Substance under WADA.

Safety Realities & Impurities

Safety depends on the molecule, formulation, route and evidence. A laboratory purity measurement alone cannot establish safety for human use.

REGISTRY CHECK

Clinical Trials Registry Records

Official registry records from ClinicalTrials.gov. Study registration does not imply government endorsement or guaranteed efficacy.

COMPETITIVE SPORT

WADA & Anti-Doping Regulations

Prohibited (S2)

WADA Section S2: Prohibited Substance

The World Anti-Doping Agency (WADA) classifies CJC-1295 under Section S2 of the Prohibited List. Prohibited at all times (in- and out-of-competition). Last verified: October 2026.

SELECTED MILESTONES

Research Timeline

  1. 2006

    Phase 1 Published

    JCEM study reports prolonged GH and IGF-I rises in healthy adults. [1]

  2. 2006

    Phase 2 Trial Terminated

    Phase 2 trial in HIV-associated visceral obesity recorded as terminated; the registry gives no reason. [2]

  3. 2026

    WADA S2 Status

    Classified under Section S2 Peptide Hormones. [3]

OPEN QUESTIONS

What Researchers Still Don't Know

Long-term safety profiles

Multi-year observational data in broader heterogeneous cohorts remains uncharacterized.

Optimal dose-response thresholds

Comparative trials optimizing minimal effective exposure versus adverse event rates.

Formulation bioavailability

Differences between oral, subcutaneous, and modified peptide delivery vehicles.

TRACEABLE SOURCES

References

Primary sources verified against PubMed / NLM and regulatory databases.

  1. Clinical Pharmacology RCT

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults ↗ (external website)

    Teichman SL et al. · J Clin Endocrinol Metab · 2006
  2. Registry Record

    A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity ↗ (external website)

    ClinicalTrials.gov · 2006
  3. Regulatory

    WADA S2 Peptide Hormones & Growth Factors ↗ (external website)

    WADA · 2026